284 related articles for article (PubMed ID: 24821107)
1. DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review).
Koukoura O; Spandidos DA; Daponte A; Sifakis S
Mol Med Rep; 2014 Jul; 10(1):3-9. PubMed ID: 24821107
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
Aref-Eshghi E; McGee JD; Pedro VP; Kerkhof J; Stuart A; Ainsworth PJ; Lin H; Volodarsky M; McLachlin CM; Sadikovic B
J Hum Genet; 2020 Oct; 65(10):865-873. PubMed ID: 32483276
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934
[TBL] [Abstract][Full Text] [Related]
4. Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia.
Pradjatmo H
Asian Pac J Cancer Prev; 2015; 16(18):8599-604. PubMed ID: 26745123
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment.
Barton CA; Hacker NF; Clark SJ; O'Brien PM
Gynecol Oncol; 2008 Apr; 109(1):129-39. PubMed ID: 18234305
[TBL] [Abstract][Full Text] [Related]
6. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
7. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P
Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291
[TBL] [Abstract][Full Text] [Related]
8. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
[TBL] [Abstract][Full Text] [Related]
9. Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
Pradhan M; Risberg BA; Tropé CG; van de Rijn M; Gilks CB; Lee CH
BMC Cancer; 2010 Sep; 10():493. PubMed ID: 20843305
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
Wang YQ; Yan Q; Zhang JR; Li SD; Yang YX; Wan XP
J Obstet Gynaecol Res; 2013 Feb; 39(2):549-54. PubMed ID: 23006047
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide DNA methylation as an epigenetic consequence of Epstein-Barr virus infection of immortalized keratinocytes.
Birdwell CE; Queen KJ; Kilgore PC; Rollyson P; Trutschl M; Cvek U; Scott RS
J Virol; 2014 Oct; 88(19):11442-58. PubMed ID: 25056883
[TBL] [Abstract][Full Text] [Related]
13. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Vieth E; Lee J; Segar M; Liu Y; Nephew KP; Matei D
Epigenetics; 2014 Nov; 9(11):1461-72. PubMed ID: 25470663
[TBL] [Abstract][Full Text] [Related]
14. Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.
Wang Z; Zhang J; Zhang Y; Deng Q; Liang H
Int J Mol Med; 2018 Dec; 42(6):3542-3550. PubMed ID: 30221688
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation and demethylation as targets for anticancer therapy.
Szyf M
Biochemistry (Mosc); 2005 May; 70(5):533-49. PubMed ID: 15948707
[TBL] [Abstract][Full Text] [Related]
16. Recently identified drug resistance biomarkers in ovarian cancer.
Davidson B
Expert Rev Mol Diagn; 2016; 16(5):569-78. PubMed ID: 26895188
[TBL] [Abstract][Full Text] [Related]
17. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer.
Wrzeszczynski KO; Varadan V; Byrnes J; Lum E; Kamalakaran S; Levine DA; Dimitrova N; Zhang MQ; Lucito R
PLoS One; 2011; 6(12):e28503. PubMed ID: 22174824
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modulation of BRCA1 and BRCA2 gene expression by equol in breast cancer cell lines.
Bosviel R; Durif J; Déchelotte P; Bignon YJ; Bernard-Gallon D
Br J Nutr; 2012 Oct; 108(7):1187-93. PubMed ID: 22217331
[TBL] [Abstract][Full Text] [Related]
19. The DNA methylome of cervical cells can predict the presence of ovarian cancer.
Barrett JE; Jones A; Evans I; Reisel D; Herzog C; Chindera K; Kristiansen M; Leavy OC; Manchanda R; Bjørge L; Zikan M; Cibula D; Widschwendter M
Nat Commun; 2022 Feb; 13(1):448. PubMed ID: 35105887
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid receptor repression mediated by BRCA1 inactivation in ovarian cancer.
Fang YY; Li D; Cao C; Li CY; Li TT
BMC Cancer; 2014 Mar; 14():188. PubMed ID: 24629067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]